Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Imcivree (Setmelanotide) is a treatment designed specifically for individuals dealing with rare genetic disorders of obesity. As a melanocortin-4 receptor (MC4R) agonist, Imcivree functions by activating the MC4R pathway, which plays a crucial role in regulating hunger and body weight. This prescription medication is targeted for use in patients with obesity due to POMC (Pro-opiomelanocortin), PCSK1 (Proprotein Convertase Subtilisin/Kexin Type 1), or LEPR (Leptin Receptor) deficiency confirmed by genetic testing. By addressing the underlying genetic conditions that affect the MC4 pathway, Imcivree helps to reduce hunger and increase feelings of fullness.
Before you buy Imcivree, it is crucial that you talk to your healthcare provider about potential side effects and Imcivree cost.
| Fact Table | |
|---|---|
| Formula | C49H68N18O9 |
| License | FDA approved |
| Bioavailability | Approximately 80% (subcutaneous) |
| Legal status | Prescription drug |
| Chemical Name | Setmelanotide |
| Elimination half-life | 33 hours (approximately) |
| Dosage (Strength) | 10 mg/mL (injection) |
| Pregnancy | Contraindicated |
| Brands | Imcivree |
| Protein binding | 80% |
| PubChem CID | 73322155 |
| MedlinePlus | Available under Setmelanotide |
| ChEBI | Not available |
| ATC code | A16AX10 |
| DrugBank | DB15500 |
| KEGG | D11389 |
| Routes of administration | Subcutaneous |
Imcivree is administered via subcutaneous injection. It is essential that the medication be administered as prescribed by a healthcare provider. The typical dosage and schedule depend on the specific needs and medical history of the patient. Patients are advised to follow a diet and exercise plan alongside their treatment. Regular follow-up appointments are crucial to monitor the treatment's effectiveness and adjust the dose if necessary.
The active ingredient in Imcivree is setmelanotide.
Patients with a known allergy to setmelanotide or any of the ingredients in Imcivree should avoid using this medication.
There is limited data on the use of Imcivree in pregnant or breastfeeding women. Use only if the potential benefit justifies the potential risk.
Safety and effectiveness in pediatric patients under six years of age have not been established.
Imcivree injection can potentially interact with other medications, which can alter how Imcivree or the other medications work. Inform your healthcare provider of all the medications you take, including prescription and over-the-counter medicines, vitamins, herbal supplements. Particular attention should be given to other medications that affect weight or appetite and medications that can affect renal function or blood pressure.
While Imcivree is effective in managing obesity related to specific genetic conditions, it can cause side effects, some of which may require medical attention. Common side effects include injection site reactions such as redness, swelling, or pain and skin pigmentation changes or darkening.
What is Imcivree?
Imcivree is the brand name for setmelanotide, a medication that targets the melanocortin 4 receptor (MC4R) pathway. It is used to treat obesity due to certain genetic conditions.
What is Imcivree used for?
Imcivree is used to manage obesity in individuals with specific genetic conditions, such as POMC (proopiomelanocortin) deficiency, PCSK1 (proprotein convertase subtilisin/kexin type 1) deficiency, and LEPR (leptin receptor) deficiency. These genetic conditions lead to severe obesity from an early age.
How does Imcivree work?
Imcivree works by activating the MC4R pathway in the brain, which helps regulate hunger and energy expenditure. By stimulating this pathway, the drug can reduce hunger and promote weight loss in individuals with genetic conditions affecting this pathway.
What are the results of Imcivree?
Clinical trials have shown that Imcivree can lead to significant weight loss in individuals with the specified genetic conditions. Patients have experienced reductions in body weight, improvements in hunger control, and better overall health outcomes.
Is Imcivree FDA approved?
Yes, Imcivree is approved by the U.S. Food and Drug Administration (FDA) for the treatment of obesity due to POMC, PCSK1, and LEPR deficiencies.
Can anyone take Imcivree?
No, Imcivree is specifically approved for use in individuals with genetic conditions such as POMC, PCSK1, and LEPR deficiencies. It is not intended for use in the general population or for individuals with obesity not related to these genetic conditions.
How to inject Imcivree?
Imcivree is administered via subcutaneous injection. Patients or caregivers are typically trained by healthcare professionals on how to properly prepare and inject the medication. It is usually injected into the abdomen, thigh, or upper arm.
What are the side effects of Imcivree?
Common side effects of Imcivree include injection site reactions, skin hyperpigmentation, nausea, headache, and fatigue. Some patients may experience changes in skin color, particularly in areas exposed to sunlight.
How often do you take Imcivree?
Imcivree is typically administered once daily. The exact dosing schedule should be determined by a healthcare provider based on the patient's individual needs and response to the treatment.
What are the adverse events of Setmelanotide?
Adverse events associated with setmelanotide (Imcivree) can include injection site reactions, skin hyperpigmentation, nausea, vomiting, headache, and fatigue. In rare cases, more serious adverse events such as depression, suicidal ideation, and hypersensitivity reactions have been reported. It's important for patients to be monitored regularly by their healthcare provider while on this medication.
